Research map: New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer

Back to the article

Papers in this map

  1. Mutations of the BRAF gene in human cancer · Helen Ruth Davies · 2002 · 10794 citations · Cited by this paper
  2. LMTK2 Inhibits Metastasis of Colon Cancer Cells Through p38 MAPK · 2026 · Related
  3. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation · Paul B. Chapman · 2011 · 7808 citations · Cited by this paper
  4. Targeting the NR3C1 ‐ ACSL4 Axis Triggers Ferroptosis to Overcome Radioresistance in Prostate Cancer · 2026 · Related
  5. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases · Rajesha Rupaimoole · 2017 · 4976 citations · Cited by this paper
  6. Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB – IIIA Non‐Small‐Cell Lung Cancer: Phase 2 neoSCORE Trial · 2026 · Related
  7. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations · Keith T. Flaherty · 2012 · 2842 citations · Cited by this paper
  8. circMAN1A2 as an Isoform‐Resolved Circular RNA Hub in Cancer · 2026 · Related
  9. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation · Ramin Nazarian · 2010 · 2213 citations · Cited by this paper
  10. RASD 2 Drives Renal Clear Cell Carcinoma Progression via RAF 1 (Ser338) Phosphorylation · 2026 · Related
  11. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR · Anirudh Prahallad · 2012 · 2095 citations · Cited by this paper
  12. Bile‐Derived Exosomal miR ‐196a/‐196b as Diagnostic Biomarkers Associated With Tumor Progression in Biliary Tract Cancer · 2026 · Related
  13. Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma · James Larkin · 2014 · 2083 citations · Cited by this paper
  14. Transporter‐Associated Therapeutic Efficacy of an SMVT ‐Targeted Boron Carrier in Boron Neutron Capture Therapy · 2026 · Related
  15. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer · Scott Kopetz · 2019 · 1507 citations · Cited by this paper
  16. Urinary Small Extracellular Vesicle DNA as a Biomarker for the Non‐Invasive Diagnosis of Bladder Cancer · 2026 · Related
  17. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma · Georgina Venetia Long · 2017 · 1504 citations · Cited by this paper
  18. Ketogenic Diet and β‐Hydroxybutyrate Suppress Bladder Cancer Growth and Enhance Anti‐ PD ‐ L1 Immunotherapy Efficacy · 2026 · Related
  19. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) · Poulikos I. Poulikakos · 2011 · 1482 citations · Cited by this paper
  20. Pleiotropic effects of all-trans retinoic acid in attenuating the hallmarks of colorectal cancer- challenges and scope of differentiation therapy · 2025 · Related
  21. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial · David Planchard · 2017 · 1391 citations · Cited by this paper
  22. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial · Reinhard Dummer · 2018 · 1046 citations · Cited by this paper
  23. EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib · Ryan Bruce Corcoran · 2012 · 1044 citations · Cited by this paper
  24. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy · Hubing Shi · 2013 · 1014 citations · Cited by this paper
  25. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer · Vivek Subbiah · 2017 · 903 citations · Cited by this paper
  26. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial · David Planchard · 2016 · 898 citations · Cited by this paper
  27. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer · Scott Kopetz · 2015 · 707 citations · Cited by this paper
  28. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance · Hubing Shi · 2012 · 644 citations · Cited by this paper
  29. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance · Willy Hugo · 2015 · 634 citations · Cited by this paper
  30. V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway · Christine A. Pratilas · 2009 · 626 citations · Cited by this paper
  31. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS · Zhan Yao · 2017 · 580 citations · Cited by this paper
  32. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations · Matthew Dankner · 2018 · 577 citations · Cited by this paper
  33. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition · Zhan Yao · 2015 · 564 citations · Cited by this paper
  34. RAF-MEK-ERK pathway in cancer evolution and treatment · Rahim Ullah · 2021 · 558 citations · Cited by this paper
  35. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer · Ryan Bruce Corcoran · 2015 · 519 citations · Cited by this paper
  36. Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma · Clara O. Montagut · 2008 · 516 citations · Cited by this paper
  37. BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition · Marco H. Hofmann · 2020 · 434 citations · Cited by this paper
  38. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study · Ryan Joseph Sullivan · 2017 · 432 citations · Cited by this paper
  39. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers · Robert J. Nichols · 2018 · 428 citations · Cited by this paper

Source: OpenAlex (CC0)